Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis

Frontiers in Immunology

Immunology

Zonggui Xie¹  Fuwen Pang¹  Jian He¹  Weicheng Zhao¹  Haihui Deng¹  Bin Chen¹  Tuantuan Chen¹  Deti Peng² 

[1] Department of Interventional Radiology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China;Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China;

关键词: hepatocellular carcinoma;    immunotherapy;    locoregional therapy;    tislelizumab;    case report;   

DOI  :  10.3389/fimmu.2023.1163656

 received in 2023-02-11, accepted in 2023-04-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundAbdominal lymph node (ALN) metastasis is associated with a poor prognosis in patients with hepatocellular carcinoma (HCC) because of the limited number of effective therapeutic options available. Immunotherapy with immune checkpoint inhibitors, such as those targeting programmed death receptor-1 (PD-1), have produced encouraging results in patients with advanced HCC. Here, we report a complete response (CR) in a patient with advanced HCC and ALN metastasis after combination treatment with tislelizumab (a PD-1 inhibitor) and locoregional therapy.Case summaryA 58-year-old man with HCC experienced progressive disease with multiple ALN metastases after undergoing transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA), and laparoscopic resection. Because the patient did not wish to receive systemic therapy, including chemotherapy and targeting therapy, we prescribed tislelizumab (as a single immunotherapeutic agent) together with RFA. After four tislelizumab treatment cycles, the patient achieved a CR without tumor recurrence for up to 15 months.ConclusionTislelizumab monotherapy can be effectively used to treat advanced HCC with ALN metastasis. Moreover, the combination of locoregional therapy and tislelizumab is likely to further increase therapeutic efficacy.

【 授权许可】

Unknown   
Copyright © 2023 Deng, Chen, Peng, He, Zhao, Chen, Xie and Pang